Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Molecular-Targeted Agents as a Novel Therapeutic Tool for Brain Metastases].

No shinkei geka. Neurological surgery - 1 Jan 2022

Iuchi Toshihiko

Abstract excerpt

Brain metastases(BM)follow the nature of the primary cancer, and understanding the associated genomic abnormalities is essential in the construction of therapeutic strategies for BM. BM showed an excellent response to EGFR-TKI, but the duration of the effect was limited to approximately one year. Despite the longer survival of patients with EGFRm BM, these tumors tended to progress to leptomeningeal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Meningeal Carcinomatosis

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 35169087
DOI: 10.11477/mf.1436204532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Molecular-Targeted Agents as a Novel Therapeutic Tool for Brain Metastases].PMID 35169087Read ↗

Immunotherapy: an emerging modality to checkmate brain metastasisSemantic proximity Read ↗

Targeted Therapy in Brain Metastases: Ready for Primetime?Semantic proximity Read ↗

[Targeted Therapies for Driver Gene Mutation-positive Lung Cancer Patients with Brain Metastasis].Semantic proximity Read ↗

[Diagnosis of brain metastases: an update in 2012].Semantic proximity Read ↗

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.Semantic proximity Read ↗

Significant benefit of high-dose furmonertinib in the treatment of leptomeningeal metastases from non-small-cell lung cancer with EGFR ex19Del mutation: Two case reports and a literature reviewSemantic proximity Read ↗

Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

[Histological and molecular analysis of brain metastases].Semantic proximity Read ↗

Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.Semantic proximity Read ↗

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.Semantic proximity Read ↗

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.